Any content you receive is for information purposes only. Always conduct your own research.*Disseminated on Behalf of Medicus Pharma Ltd.
Paul Prescott Puts (MDCX) Back On The Top Of This Morning's Watchlist—Thursday, January 22, 2026
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Full Coverage Starting Now
Pull Up (MDCX) While It's Still Early…
January 22, 2026
Ringing the Nasdaq Bell Today | (MDCX) is Getting Early Coverage Right Now Dear Reader, This morning, January 22, 2026, we will have all eyes on Times Square as Medicus Pharma Ltd. (NASDAQ: MDCX) Executive Chairman and CEO Dr. Raza Bokhari rings the Opening Bell at the Nasdaq MarketSite. This prestigious ceremony doesn't just celebrate the company's first anniversary on the exchange—it signals its formal arrival as a diversified, multi-asset biotech player ready to hit our watchlist. This high-visibility milestone follows a rapid-fire sequence of developments that have pushed Medicus Pharma Ltd. (NASDAQ: MDCX) to the top of our radar heading into today's session—Thursday, January 22, 2026: - AI Integration: On December 22, 2025, (MDCX) announced a strategic engagement with Reliant AI to build an AI-driven clinical data analytics platform. By utilizing advanced machine learning for site selection and patient stratification, the company is modernizing its development of Teverelix, ensuring capital-efficient execution as it scales.
- Clinical Breakthrough in Women's Health: Just last week, on January 12, 2026, the company demonstrated that Teverelix achieves rapid hormone suppression while maintaining stable bone turnover in women. This critical safety validation paves the way for a Phase 2 trial in the $2B+ endometriosis market, significantly expanding the commercial potential.
- SkinJect Topline Results Imminent: These updates arrive as the company's lead program, SkinJect, approaches its most significant potential catalyst to date. With the U.S. Phase 2 study of 90 patients now fully enrolled, "decision-grade" topline results are expected in Q1 2026.
But keep in mind, (MDCX) is working with an ultra-thin float of under 8M shares according to MarketWatch. When companies have small floats like this, the potential exists for big moves if demand begins to shift. With insider ownership north of 30%—the kind of alignment that often signals confidence behind the scenes—and you can see why momentum watchers are paying attention again. All signs point to a setup worth a closer look. Analyst Targets Suggests Over 800% to 2,000%
Upside Potential From Recent Range… Multiple market outlets, including Benzinga, MarketWatch, and TipRanks, have reported that D. Boral Capital analyst Jason Kolbert recently set a $27 target on (MDCX), suggesting over 2,000% upside potential from its recent $1.28 range.
That's not the only target now in play. Brookline Capital's Kumaraguru Raja recently raised his target from $12 to $20, which suggests over 1,400% upside potential. Last week, Maxim Group's Jason McCarthy reiterated a $12 target in a report —reflecting continued confidence and over 800% upside potential from current levels. Following its recent acquisition of Antev Limited, (MDCX) has expanded into two late-stage therapeutic programs addressing major clinical needs. With analyst coverage, regulatory progress, and technical momentum all converging, (MDCX) stands out as one of the biotech names to watch heading into this morning's session. FDA Clears Streamlined Path for SkinJect's Next Phase
Medicus Pharma Ltd. (NASDAQ: MDCX) received positive Type C meeting feedback from the U.S. FDA for its SkinJect program—a dissolvable microneedle patch being developed to non-invasively treat basal cell carcinoma (BCC). The agency confirmed that the program may follow the streamlined 505(b)(2) pathway, potentially reducing both cost and development time, and also offered guidance on study design, endpoints, and formulation improvements, including an adhesive layer and applicator system. (MDCX) is advancing two Phase 2 trials: SKNJCT-003 in the U.S., now over 75% enrolled following a strong interim readout, and SKNJCT-004 across six clinical sites abroad. Enrollment for SKNJCT-003 is expected to complete before the end of Q4 2025, with an End-of-Phase-2 FDA meeting targeted for Q1 2026. The company estimates the market for non-invasive BCC treatments could approach $2B annually. Executive Chairman and CEO Dr. Raza Bokhari noted that the FDA's feedback "marks an important step toward establishing SkinJect as a potential first-in-market, non-invasive therapy for BCC," reinforcing growing confidence as development advances. (MDCX) Opens New Pathway for Patients With
Compassionate Use Partnership
Medicus Pharma Ltd. (NASDAQ: MDCX) announced a collaboration with the Gorlin Syndrome Alliance (GSA) to pursue a compassionate use pathway for its investigational SkinJect™ microneedle patch in patients with Gorlin Syndrome, a rare genetic condition affecting roughly 1 in 31,000 people worldwide. The partnership will jointly advance an Expanded Access IND Program with the FDA, allowing eligible patients with multiple or inoperable basal cell carcinomas to access SkinJect™ under physician supervision. The initiative also aims to collect real-world safety data while incorporating patient insights into ongoing development. Executive Chairman and CEO Dr. Raza Bokhari noted that the collaboration reflects (MDCX)'s mission to bring targeted innovation to conditions with significant unmet medical needs. First Patient Treated in UAE Marks Key Milestone in
Global Phase 2 Expansion Medicus Pharma Ltd. (NASDAQ: MDCX) announced that its first patient has been treated in the UAE SKNJCT-004 Phase 2 study for its SkinJect program—designed to non-invasively treat basal cell carcinoma (BCC). Cleveland Clinic Abu Dhabi is serving as the principal investigator, with additional recruitment planned across five major regional hospitals including Sheikh Shakbout Medical City and American Hospital Dubai. The study will enroll 36 participants across six UAE sites, coordinated by Insights Research Organization and Solutions (IROS), a member of the M42 healthcare portfolio. According to Dr. Raza Bokhari, Executive Chairman and CEO, this milestone "marks an important step in expanding Medicus's clinical footprint beyond the U.S.," underscoring the company's push to position SkinJect as a potential first-in-market non-invasive treatment for BCC—a global condition representing more than $2B in annual market potential. (MDCX) Bolsters Clinical Portfolio With Teverelix
—A Dual-Use Phase 2b Candidate
Medicus Pharma (NASDAQ: MDCX) has completed its acquisition of Antev Limited, gaining control of Teverelix trifluoroacetate, a next-generation GnRH antagonist in late-stage development for both acute urinary retention (AURr) and high cardiovascular-risk prostate cancer. The move broadens (MDCX)'s clinical scope into two therapeutic areas with a combined $6B market potential.
Teverelix is designed for dual use: in AURr, a condition with high recurrence rates, it aims to become the first product to prevent relapse, supported by an FDA-cleared Phase 2b study of 390 patients. In prostate cancer patients with elevated cardiovascular risk, it is being evaluated in another FDA-cleared Phase 2b trial as a potentially safer alternative to conventional therapies. The acquisition also adds leadership depth, with veteran pharma executive Patrick J. Mahaffy joining the board. Together, the expanded pipeline and strengthened leadership put (MDCX) in position to reshape care across two areas of pressing medical need. 7 Key Drivers Putting (MDCX) On The Top Of This Morning's
Watchlist —Thursday, January 22, 2026
1. Analyst Coverage: multiple firms have issued targets at $12 and as high as $27, framing expectations for (MDCX) that suggest roughly 800% to 2,000% upside potential from its recent range.
2. Limited Float: with fewer than 8M shares available, (MDCX)'s small float has the potential for big moves if demand begins to shift. 3. Insider Confidence: leadership continues to hold more than 30% of (MDCX)'s float, reinforcing long-term confidence behind the scenes. 4. AI Execution: advanced machine-learning tools are now being applied to clinical site selection and patient stratification, positioning (MDCX) to modernize how its Teverelix program scales efficiently. 5. Near-Term Readout: fully enrolled Phase 2 trials set the stage for decision-grade topline data in Q1 2026, placing (MDCX) at a pivotal moment across its lead SkinJect program.
6. FDA Progress: positive Type C feedback supports a streamlined 505(b)(2) path for SkinJect, giving (MDCX) clearer regulatory direction with specific guidance on trial design, endpoints, and formulation upgrades. 7. Ringing the Nasdaq Bell: with Executive Chairman and CEO Dr. Raza Bokhari set to ring the Nasdaq Opening Bell this morning, January 22, 2026, (MDCX) is stepping into a high-visibility moment that underscores its growing presence on the national stage. All seven factors point to one conclusion—(MDCX) is entering a decisive stretch. With multiple potential catalysts aligning across its pipeline, this morning stands out as a moment to keep (MDCX) at the top of your radar. Pull Up (MDCX) While It's Still Early…
When multiple signals start stacking like this, it usually means the story is entering a higher-definition phase. With targets ranging from $12 to $27 (which suggests 800% to 2,000% upside potential) circulating across the Street, a float under 8M shares, and insiders holding more than 30% of shares, (MDCX) already checks several "pay attention" boxes. And this morning adds a rare spotlight moment—Executive Chairman and CEO Dr. Raza Bokhari is scheduled to ring the Nasdaq Opening Bell in Times Square, putting (MDCX) on a much bigger stage right as the narrative tightens. Now layer in the operational shift: the company is bringing AI and machine-learning tools into trial execution for Teverelix—aimed at smarter site selection and tighter patient stratification—while recent women's health data adds a meaningful safety validation that points toward a Phase 2 path in endometriosis. At the same time, SkinJect is approaching decision-grade topline data in Q1 2026, supported by a clearer FDA roadmap under the 505(b)(2) framework. (MDCX) is our top priority this morning—Thursday, January 22, 2026. Turn on the TV and watch (MDCX) ring the bell at the Nasdaq MarketSite. Also, watch for my next update, it could be on its way within the next 60-90 minutes. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter
| 
